Oncternal Therapeutics Inc. (ONCT) Misses Q3 EPS by 2c

Oncternal Therapeutics Inc. (NASDAQ: ONCT) reported Q3 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $180 thousand versus the consensus estimate of $125 thousand.

For earnings history and earnings-related data on Oncternal Therapeutics Inc. (ONCT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
• KeyBanc Upgrades Acadia Realty Trust (AKR) to Overweight